Advertisement

Topics

ADMA nets $34.56mm in follow-on offering

14:40 EST 10 Nov 2017 | Elsevier Business Intelligence

ADMA Biologics Inc. (plasma-based therapies for primary immune deficiency disease (PIDD) netted $34.56mm through a public off...

Original Article: ADMA nets $34.56mm in follow-on offering

NEXT ARTICLE

More From BioPortfolio on "ADMA nets $34.56mm in follow-on offering"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...